Tadocizumab  (Synonyms: C4G1; YM-337)

Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research^[1][2].

Tadocizumab (YM-337) significantly inhibits ex vivo ADP-induced platelet aggregation, and completely inhibits arachidonic acid-induced platelet aggregation^[1].
Tadocizumab (YM-337) inhibits human platelet adhesion to von Willebrand factor, fibrinogen, fibronectin and subendothelial matrix^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tadocizumab (YM-337; C4G1) dose-dependently inhibits ex vivo platelet aggregation, with complete inhibition at doses higher than 0.25 mg/kg intravenous injection or 1.5 μg/kg/min infusion in rhesus monkeys^[1].
Tadocizumab (YM-337; C4G1) at a dose of 1 mg/kg intravenous injection followed by 6 μg/kg/min infusion for 60 min prevented occlusive thrombus formation in monkeys, in a photochemically-induced thrombosis model in squirrel monkeys^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

339086-80-5

[Tadocizumab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. S Kaku, et al. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. Thromb Haemost. 1996 Apr;75(4):679-84.  [Content Brief]

  [2]. Ken-ichi Suzuki, et al. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties. Biol Pharm Bull. 2002 Aug;25(8):1006-12.  [Content Brief]